According to Bharat Biotech, Covaxin is showing sufficient immunity against different coronavirus variants including the UK strain.
New Delhi| Bharat Biotech’s Coronavirus vaccine- Covaxin, was found to be 81 per cent effective in its Phase III trial. The company has given this information by issuing a statement on Wednesday evening. The Indian government approved the emergency use of the Coronavirus vaccine of 2 manufacturers a few months ago. Currently, only Covishield of Serum Institute of India and Bharat Biotech’s Covaxin are being administered in the country.
According to the Hyderabad-based company, the trial involved 25,800 people, making it the largest number of clinical trial participants in India so far. The company completed the clinical trial with the help of the Indian Council for Medical Research. Krishna Ella, the company’s chairman, said, “Today has proved to be a milestone in the fight against Corona and the discovery of the vaccine. After the results of the Phase 3 clinic trial, we now have the results of the trial of a total of 27,000 people including Phase-1, 2, 3.”
A great win for Atmanirbhar Bharat! India’s indigenously developed #COVAXIN shows 81% interim efficacy in Phase 3 trial. We are now one step closer to winning the fight against COVID-19. #Unite2FightCOVID @MoHFW_India @PMOIndia @drharshvardhan @PIB_India @BharatBiotech pic.twitter.com/jVKYy0Tsm1
— ICMR (@ICMRDELHI) March 3, 2021
Trial of nasal vaccine may start next week!
According to Bharat Biotech, Covaxin has proved to be effective against the coronavirus to a great extent. Along with this, it is showing sufficient immunity against different coronavirus variants including the UK strain. Experts and opposition parties had raised questions over the non-completion of Phase III trial when the govt approved the vaccine for emergency use. On March 1, in the second phase of vaccination, PM Modi had also received Covaxin jab.
Also Read: PM Modi Gets Coronavirus Vaccine As Second Phase of Inoculation Begins In India
After completion of the phase 3 trial of the Coronavirus vaccine through biotech injection, India is now starting the trial of the nasal coronavirus vaccine. According to reports, Bharat Biotech is going to start a trial of the nasal vaccine in cities like Patna, Nagpur, Chennai from next week. It is believed that only one dose of nasal vaccine will be effective in the fight against Coronavirus.
As an independent media platform, we do not take advertisements from governments and corporate houses. It is you, our readers, who have supported us on our journey to do honest and unbiased journalism. Please contribute, so that we can continue to do the same in future.
